Loading organizations...

§ Private Profile · San Francisco, CA, USA
Synthetic biology company engineering optimized mammalian cell lines for gene therapy manufacturing, focused on viral vector production.
64x Bio has raised $60.0M across 2 funding rounds.
Key people at 64x Bio.
64x Bio was founded in 2017 by Lexi Rovner (Co-founder & CEO).
64x Bio has raised $60.0M in total across 2 funding rounds.
Based in San Francisco, California, 64x Bio is a synthetic biology company that develops advanced cell lines to optimize the manufacturing of viral vectors for gene therapies. The biotechnology firm utilizes its proprietary VectorSelect platform and AAV Apex Suite to engineer mammalian cells capable of producing complex therapeutics at scale. Operating as a business-to-business platform, the company provides its high-throughput discovery technologies to pharmaceutical companies, biotechnology firms, and contract development and manufacturing organizations. The enterprise operates with approximately 25 employees and has secured $59.6 million in total venture funding to date. 64x Bio is backed by prominent venture capital investors including Andreessen Horowitz, First Round Capital, and Lifeforce Capital. The company was founded in 2017 as a spinout from Harvard University's Wyss Institute by Lexi Rovner, George Church, David Thompson, and Pamela Silver.
Key people at 64x Bio.
64x Bio has raised $60.0M across 2 funding rounds. Most recently, it raised $55.0M Series A in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2022 | $55M Series A | Sander Duncan | Cathay Innovation, Franck LE Ouay, Michael Chambers, Alix Ventures, BoxGroup, Fifty Years, First Round Capital, Future Ventures, Northpond Ventures, Refactor Capital, SV Angel | Announced |
| Nov 1, 2020 | $5M Seed | Fifty Years, First Round Capital, Refactor Capital | Seven Seven SIX, Y Combinator, Seth Goldman | Announced |
64x Bio is a biotechnology company developing a comprehensive platform to accelerate and optimize the manufacturing of cell and gene therapies. Their proprietary VectorSelect™ platform uses high-throughput genome engineering, genetic barcoding, and machine learning to discover and engineer highly optimized mammalian cell lines for viral vector production. This innovation reduces the cost, complexity, and time of manufacturing, enabling pharmaceutical and biotechnology companies to bring more advanced therapies to patients and expand into broader biologics markets such as vaccines and oncolytic therapies[1][2][6].
---
---
64x Bio was founded in 2017 as a spinout from Harvard’s Wyss Institute and George Church’s lab, leveraging breakthrough cellular screening and genome engineering technologies developed there[1][3]. The founding team combined expertise in synthetic biology, genome engineering, and computational biology to address the critical manufacturing bottleneck in cell and gene therapies. Early traction included securing substantial Series A funding ($55M in 2022) and validation from industry leaders, enabling rapid platform development and commercial partnerships[2][8].
---
---
64x Bio rides the wave of rapid growth in cell and gene therapies, a multibillion-dollar market constrained by manufacturing bottlenecks. The timing is critical as the industry shifts from clinical trials to commercial-scale production, demanding scalable, cost-effective solutions[1][6]. Advances in genome engineering, high-throughput screening, and AI-driven design loops position 64x Bio at the forefront of biomanufacturing innovation. Their platform not only accelerates therapy availability but also influences the broader ecosystem by enabling new biologics and expanding the reach of advanced therapies[1][3].
---
Looking ahead, 64x Bio is poised to expand its platform capabilities and market reach, including launching specialized suites like the AAV Apex Suite for gene therapy manufacturing at scale[8][6]. Trends shaping their journey include increasing demand for scalable viral vector production, integration of AI in biologics design, and growing investment in next-generation therapies. Their influence is likely to grow as they enable more efficient manufacturing, reduce costs, and unlock new therapeutic indications, reinforcing their role as a key enabler in the future of medicine[1][8].
This trajectory ties back to their mission of transforming how lifesaving cell and gene therapies are made, ultimately accelerating patient access to next-generation medicines.
64x Bio was founded in 2017 by Lexi Rovner (Co-founder & CEO).
64x Bio has raised $60.0M in total across 2 funding rounds.
64x Bio's investors include Sander Duncan, Cathay Innovation, Franck Le Ouay, Michael Chambers, Alix Ventures, BoxGroup, Fifty Years, First Round Capital, Future Ventures, Northpond Ventures, Refactor Capital, SV Angel.